insights_auto
Why is TGNA down 2.64%?
Dive Deeperchevron_right
TGNA:FRA
Transgene SA
€0.66
arrow_downward
-2.64%(-0.018) 1D
Oct 9, 8:01:35 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
€0.66
High
€0.66
Low
€0.66
Mkt. cap
193.58M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
160
Open
€0.66
High
€0.66
Low
€0.66
Mkt. cap
193.58M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
160
News stories
From web sources and news partners
BigGo Finance
·
57 minutes ago
Dow extends gains, climbs back above 51,300 on tech buybacks; SpaceX briefly up 3%
36Kr
·
57 minutes ago
Can the US Stock Bull Market Still Continue? 2025 Outlook, Key Drivers & Future Trend Analysis
ChartMill
·
2 hours ago
These S&P500 stocks are gapping in today's session
The Motley Fool
·
44 minutes ago
I've Owned the Vanguard S&P 500 ETF for 6 Years. Here's Why I'm Not Selling.
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA